JP2019500347A5 - - Google Patents

Download PDF

Info

Publication number
JP2019500347A5
JP2019500347A5 JP2018529240A JP2018529240A JP2019500347A5 JP 2019500347 A5 JP2019500347 A5 JP 2019500347A5 JP 2018529240 A JP2018529240 A JP 2018529240A JP 2018529240 A JP2018529240 A JP 2018529240A JP 2019500347 A5 JP2019500347 A5 JP 2019500347A5
Authority
JP
Japan
Prior art keywords
protein
mrna
prpf8
pharmaceutical composition
nucleobases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018529240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500347A (ja
JP7054675B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/066684 external-priority patent/WO2017106364A2/en
Publication of JP2019500347A publication Critical patent/JP2019500347A/ja
Publication of JP2019500347A5 publication Critical patent/JP2019500347A5/ja
Priority to JP2022062557A priority Critical patent/JP2022088621A/ja
Application granted granted Critical
Publication of JP7054675B2 publication Critical patent/JP7054675B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018529240A 2015-12-14 2016-12-14 網膜色素変性症１８と網膜色素変性症１３の処置のための組成物と方法 Expired - Fee Related JP7054675B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022062557A JP2022088621A (ja) 2015-12-14 2022-04-04 網膜色素変性症１８と網膜色素変性症１３の処置のための組成物と方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267261P 2015-12-14 2015-12-14
US62/267,261 2015-12-14
PCT/US2016/066684 WO2017106364A2 (en) 2015-12-14 2016-12-14 Compositions and methods for treatment of retinitis pigmentosa 18 and retinitis pigmentosa 13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022062557A Division JP2022088621A (ja) 2015-12-14 2022-04-04 網膜色素変性症１８と網膜色素変性症１３の処置のための組成物と方法

Publications (3)

Publication Number Publication Date
JP2019500347A JP2019500347A (ja) 2019-01-10
JP2019500347A5 true JP2019500347A5 (https=) 2020-01-30
JP7054675B2 JP7054675B2 (ja) 2022-04-14

Family

ID=59057547

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018529240A Expired - Fee Related JP7054675B2 (ja) 2015-12-14 2016-12-14 網膜色素変性症１８と網膜色素変性症１３の処置のための組成物と方法
JP2022062557A Pending JP2022088621A (ja) 2015-12-14 2022-04-04 網膜色素変性症１８と網膜色素変性症１３の処置のための組成物と方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022062557A Pending JP2022088621A (ja) 2015-12-14 2022-04-04 網膜色素変性症１８と網膜色素変性症１３の処置のための組成物と方法

Country Status (5)

Country Link
EP (1) EP3390642B1 (https=)
JP (2) JP7054675B2 (https=)
CA (1) CA3005254A1 (https=)
ES (1) ES2903394T3 (https=)
WO (1) WO2017106364A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
CN107109411B (zh) 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
EP3359685B1 (en) 2015-10-09 2026-01-28 University Of Southampton Modulation of gene expression for deregulated protein expression
EP3933041B1 (en) 2015-12-14 2024-01-31 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant retardation
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
AU2017229778A1 (en) 2016-03-09 2018-08-16 Ionis Pharmaceuticals, Inc. Methods and compositions for inhibiting PMP22 expression
IL314915B1 (en) 2017-01-23 2026-02-01 Regeneron Pharma Variants of 17-beta-hydroxysteroid dehydrogenase and their uses
KR20190139869A (ko) 2017-04-11 2019-12-18 리제너론 파마슈티칼스 인코포레이티드 하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정
SG11202001590RA (en) 2017-08-25 2020-03-30 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
US10961583B2 (en) 2017-10-11 2021-03-30 Regeneron Phramaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
JP7532257B2 (ja) * 2018-03-02 2024-08-13 アカデミシュ・ジークンホイス・ライデン・ハー・オー・デー・エン・ライドス・ユニヴェルシタイル・メディシュ・セントルム ポリオーマウイルス複製の阻害
JP7507093B2 (ja) 2018-03-21 2024-06-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド １７β－水酸化ステロイド脱水素酵素１３型（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物およびその使用方法
US12060558B2 (en) 2018-05-04 2024-08-13 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
WO2020132558A1 (en) * 2018-12-21 2020-06-25 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing pmp22 expression
KR20210134003A (ko) 2019-02-27 2021-11-08 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 안티센스 올리고머
BR112022022889A2 (pt) 2020-05-11 2023-04-04 Stoke Therapeutics Inc Oligômeros antissentido de opa1 para tratamento de condições e doenças

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866042A (en) 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
US6294520B1 (en) 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
EP0669987B1 (en) 1992-09-25 2008-08-13 Aventis Pharma S.A. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
US5656612A (en) 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
FR2727867B1 (fr) 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
US6936589B2 (en) 2001-09-28 2005-08-30 Albert T. Naito Parenteral delivery systems
WO2007047913A2 (en) 2005-10-20 2007-04-26 Isis Pharmaceuticals, Inc Compositions and methods for modulation of lmna expression
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
PT3305302T (pt) 2009-06-17 2018-12-14 Biogen Ma Inc Composições e métodos de modulação de excisões de smn2 em um sujeito
AU2012284265B2 (en) 2011-07-19 2017-08-17 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
CN103667438B (zh) * 2013-01-07 2015-04-01 赵晨 一种筛查HRDs致病突变的方法及涉及的基因芯片杂交探针设计方法
PL3041958T4 (pl) 2013-09-04 2020-11-02 Cold Spring Harbor Laboratory Redukcja rozpadu mRNA mediowanego sekwencjami nonsensownymi

Similar Documents

Publication Publication Date Title
JP2019500347A5 (https=)
JP2019501892A5 (https=)
JP7420679B2 (ja) 状態および疾患の処置のためのアンチセンスオリゴマー
JP2022062140A5 (https=)
JP2024056778A5 (https=)
JP2019500346A5 (https=)
JP2018538288A5 (https=)
JP2018538287A5 (https=)
JP2019500349A5 (https=)
FI3700570T3 (fi) Antisense-oligomeerejä nonsense-välitteiseen rna:n hajoamiseen pohjautuvien tilojen ja sairauksien hoitoon
JP7054675B2 (ja) 網膜色素変性症１８と網膜色素変性症１３の処置のための組成物と方法
JP2017519766A5 (https=)
JP2019500350A5 (https=)
EP2516647B1 (en) Molecule for treating an inflammatory disorder
JP2017536338A5 (https=)
JP2019500345A5 (https=)
US20120270930A1 (en) Methods and compositions for dysferlin exon-skipping
TWI901675B (zh) 用於病症及疾病之治療的opa1反義寡聚物
JP2022046723A (ja) 多発性嚢胞腎の処置のためのアンチセンスオリゴマー
KR20080031164A (ko) ＳＲ 단백질의 결합의 방해에 의해 그리고 이차 ＲＮＡ구조의 방해에 의한 ｐｒｅ－ｍＲＮＡ에서 엑손 인식의조절
EP3390635A1 (en) Antisense oligomers for treatment of tuberous sclerosis complex
US20200407721A1 (en) Compounds of chemically modified oligonucleotides and methods of use thereof
JP2024079818A (ja) コレステリルエステル蓄積症の処置のための方法及び組成物
JP2021523227A5 (https=)
CN101736003B (zh) 日本血吸虫miRNA及其应用